Infective Endocarditis: Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Infective endocarditis (IE) is a life-threatening infection of the endocardial surface of the heart — most commonly the cardiac valves (native or prosthetic), but also the mural endocardium, septal defects, or indwelling intracardiac devices (pacemaker/ICD leads, prosthetic valve sewing rings). It is characterized by microbial colonization of a fibrin-platelet vegetation on damaged or abnormal endothelium, producing local tissue destruction (valve regurgitation/perforation, abscess), immune-mediated phenomena (glomerulonephritis, vasculitic skin/eye lesions), and systemic septic embolization. The StatPearls overview states plainly: "Infective endocarditis is an inflammatory condition of the endocardium, the inner lining of the heart, including the valves" (PMID not separately assigned to StatPearls chapter; NCBI Bookshelf NBK557641). A 2020 review states "Infective endocarditis (IE) is an infection of the endothelium of the heart" with an annual incidence of 3–10/100,000 population and mortality "of up to 30% at 30 days" (PMID:31941729).

Key identifiers: - MONDO: MONDO:0000565 (infective endocarditis) - OMIM: No single-gene Mendelian OMIM phenotype entry exists for IE itself (it is not a monogenic disorder); OMIM entries are relevant only for underlying predisposing structural/connective-tissue conditions (e.g., bicuspid aortic valve, Marfan syndrome, hypertrophic cardiomyopathy) - Orphanet: Not a rare/orphan disease per se (common acquired infection); Orphanet indexes it primarily under structural/valvular predisposition syndromes rather than as its own ORPHA entity - ICD-10-CM: I33.0 (Acute and subacute infective endocarditis); I38 (Endocarditis, valve unspecified); I39 (Endocarditis and heart valve disorders in diseases classified elsewhere) - ICD-11: BC63 (Infective endocarditis) - MeSH: D004696 (Endocarditis, Bacterial) / D004697 (Endocarditis, Subacute Bacterial) - Synonyms: Bacterial endocarditis, infectious endocarditis, subacute bacterial endocarditis (SBE), acute bacterial endocarditis (ABE), infective endocarditis (IE), endocarditis lenta (historical)

Data derivation. Knowledge about IE derives predominantly from aggregated disease-level clinical resources: multicenter prospective cohorts (e.g., the International Collaboration on Endocarditis — ICE-PCS registry), population-level epidemiologic surveillance (Global Burden of Disease, national hospital discharge/administrative databases), and clinical trial/guideline literature (AHA, ESC), rather than from individual case-level curated genetic databases as would apply to a monogenic disease. Some individual EHR-derived cohort statistics are cited below (e.g., Swedish national registry, U.S. NIS/IQVIA claims data).

2. Etiology

Disease Causal Factors

IE is fundamentally an infectious disease requiring two converging processes: (1) an abnormal/damaged endocardial surface that generates a nidus of sterile platelet-fibrin thrombus (non-bacterial thrombotic endocarditis, NBTE), and (2) transient or sustained bacteremia/fungemia that seeds that nidus. It is not a genetic (Mendelian) disease, but genetic and structural cardiac factors substantially modify individual risk.

Causative microorganisms and approximate proportions (PMID:31941729; StatPearls NBK557641; PMC6964163): - Staphylococcus aureus — ~26.6–30% of cases (now the single most common pathogen overall, and dominant in healthcare-associated/IVDU-associated IE); associated with the most aggressive, acute presentation and worst outcomes - Viridans group streptococci (S. sanguinis, S. mitis, S. oralis, S. mutans, etc.) — ~18.7–20%; classic cause of subacute native-valve, community-acquired IE originating from the oral cavity - Other streptococci (including Streptococcus gallolyticus [bovis], associated with colonic neoplasia) — ~17.5% - Enterococci (E. faecalis, E. faecium) — ~10.5%, increasing in proportion, linked to rising antimicrobial use and healthcare exposure - Coagulase-negative staphylococci (S. epidermidis and others) — dominant cause of early prosthetic-valve IE - HACEK organisms (Haemophilus, Aggregatibacter [formerly Actinobacillus], Cardiobacterium, Eikenella, Kingella) — fastidious oral-cavity Gram-negative commensals, a classic cause of culture-negative or slow-growing-culture IE - Fungi (predominantly Candida spp., especially C. albicans, also C. parapsilosis, C. tropicalis, C. glabrata) — ~1–3% of all IE but with mortality >70% hospital-mortality rates cited at 33–47%; strongly associated with prosthetic valves, cardiac implantable devices, and injection drug use - Culture-negative organisms requiring specialized serology/PCR: Coxiella burnetii (Q fever — "the most frequent etiological agent of blood culture-negative infective endocarditis worldwide"), Bartonella spp. (B. henselae, B. quintana — biofilm-associated, linked to homelessness/body lice exposure), Tropheryma whipplei (Whipple disease), Brucella spp., Legionella, and non-Candida fungi - "Together [staphylococci, streptococci, and enterococci] account for 80–90% of all cases" (PMID:31941729)

Risk Factors

Genetic/host risk factors: - Congenital structural cardiac lesions: bicuspid aortic valve (BAV; prevalence 0.5–2.0% of the population, IE incidence 1.8–2% in BAV patients, "the risk of IE can be increased more than 140 times by congenital heart disease"), unrepaired cyanotic congenital heart disease, ventricular septal defect, patent ductus arteriosus - Connective-tissue/valvulopathy syndromes predisposing via myxomatous degeneration: mitral valve prolapse (MVP), Marfan syndrome (FBN1), Loeys-Dietz syndrome - Prior rheumatic heart disease (chronic streptococcal valvular scarring) - Hypertrophic obstructive cardiomyopathy (turbulent flow across LVOT) - Host innate-immunity gene polymorphisms modifying susceptibility once bacteremic: functional variants in TLR2 and TLR5 ("TLR polymorphisms... have been strongly associated with increased susceptibility to IE"), IL6 (the IL6 c.471+870G>A genotype associated with increased susceptibility), IL1B, IL10, IL12B, TNF, SELE (E-selectin), and ICAM1, implicating dysregulated innate immunity/cytokine signaling and endothelial adhesion pathways (PMID:25360655 [Genetic Variants in Genes of the Inflammatory Response in Association with Infective Endocarditis, PLOS ONE]). A genome-wide association study of S. aureus native-valve IE (67 cases vs. 72 S. aureus-bacteremic controls without IE) identified four SNPs on chromosome 3 approaching but not reaching genome-wide significance (P<1×10⁻⁵), underscoring that host genetic architecture of susceptibility remains incompletely defined (PMC5893849).

Environmental/acquired risk factors: - Injection drug use (IDU/IVDU): "a 50- to 100-fold higher incidence of IE compared to the general population," via endothelial injury from injected particulate matter, direct inoculation of skin/oral flora (notably S. aureus), and vasospasm-induced intimal damage; disproportionately causes right-sided (tricuspid) IE - Prosthetic heart valves (mechanical or bioprosthetic): incidence 0.3–1.2% per patient-year; highest risk in the first 6–12 months post-implantation (early PVE, dominated by coagulase-negative staphylococci and perioperative contamination) vs. late PVE (organism spectrum resembling native-valve IE) - Cardiac implantable electronic devices (CIEDs): pacemakers, ICDs — lead-associated infection and device-pocket seeding - Chronic hemodialysis (repeated vascular-access bacteremia) - Poor dentition/periodontal disease and invasive dental procedures (viridans streptococcal bacteremia) - Advanced age (rising incidence in the 55+ population — see Epidemiology) - Immunocompromised states, including HIV infection, diabetes mellitus (affecting up to one-third of North American IE patients), chronic liver disease, malignancy - Indwelling central venous catheters, healthcare-associated bacteremia, recent cardiac surgery/transcatheter valve implantation (TAVI) - Male sex (male:female ratio ~3:2, ranging 3:2 to 9:1 across series)

Protective Factors

No well-established genetic protective variants have been robustly replicated for IE specifically. General protective factors are indirect: good oral hygiene/regular dental care (reduces bacteremic seeding events), harm-reduction practices in people who inject drugs (sterile injection equipment, supervised consumption sites — reduces endothelial injury and inoculation), prompt treatment of S. aureus bacteremia to prevent secondary valve seeding, and (controversially) antibiotic prophylaxis before invasive dental procedures in high-risk cardiac-lesion patients (discussed under Prevention).

Gene-Environment Interactions

The clearest gene-environment interaction model in IE is a "two-hit" framework: an anatomic/structural or genetically-determined endocardial abnormality (bicuspid valve, MVP, prosthetic material) creates the substrate for NBTE formation, while an environmentally-determined bacteremic event (dental procedure, IDU, catheter-associated infection, dialysis access) provides the inoculum. Superimposed on this, polymorphisms in innate-immune genes (TLR2/TLR5, IL6, IL10) appear to modulate whether transient bacteremia in a structurally predisposed host progresses to established valvular infection versus is cleared — i.e., a genetic modifier of the environmentally-triggered infectious event, rather than a primary causal genetic lesion.

3. Phenotypes

IE phenotypes span constitutional/systemic symptoms, cardiac signs, immune-complex-mediated peripheral stigmata, embolic phenomena, and laboratory abnormalities.

Table (click to expand)

Phenotype	Type	Frequency	Onset/Course	HPO term (suggested)
Fever	Symptom/sign	>95% of cases ("Fever...is present in more than 95% of cases")	Acute (S. aureus) or subacute/low-grade (viridans strep); often the presenting complaint	HP:0001945 (Fever)
New or changing heart murmur	Clinical sign	~48–85% (varies by valve/organism)	Progressive as vegetation/regurgitation worsens	HP:0031264 (Cardiac murmur)
Splinter hemorrhages	Physical/dermatologic sign	~15% (nonspecific)	Subacute; immune-complex or micro-embolic	HP:0100651 (Nail dysplasia) — no exact term; closest is HP:0040242 (splinter hemorrhage not in core HPO; consider free-text)
Osler nodes	Physical sign	~3–15%, more with subacute disease	Tender, painful, immune-complex-mediated	HP:0100547 (Osler node — not standard HPO ID; confirm via OAK lookup)
Janeway lesions	Physical sign	~5–10%	Non-tender, embolic/microabscess-mediated, seen more in acute S. aureus IE	HP:0200042 (Skin ulcer) — nearest generic; verify precise term
Roth spots	Ocular sign	~2–10%	Retinal hemorrhage with pale center, immune-complex-mediated	HP:0025230 (Roth spot)
Splenomegaly	Sign	~20–40%	Subacute/chronic disease	HP:0001744 (Splenomegaly)
Petechiae (conjunctival/mucosal/extremity)	Sign	~20–40%	Variable	HP:0000967 (Petechiae)
Glomerulonephritis (immune-complex)	Renal/laboratory	Variable, part of classic triad	Subacute course	HP:0000099 (Glomerulonephritis)
Arthralgia/myalgia	Symptom	~15–30%	Nonspecific systemic	HP:0002829 (Arthralgia)
Weight loss/malaise/night sweats	Constitutional symptom	Common in subacute disease	Insidious	HP:0001824 (Weight loss); HP:0001744
Acute/worsening heart failure	Clinical sign/complication	Leading cause of morbidity and the "dominant predictor for 30-day mortality"	Can be abrupt (acute regurgitation, chordal rupture)	HP:0001635 (Congestive heart failure)
Embolic stroke/neurological event	Complication	15–30% (up to 60% with vegetations >30mm)	Can be presenting event	HP:0001297 (Stroke)
Anemia (normocytic, of chronic disease)	Laboratory abnormality	Common in subacute IE	Progressive with disease duration	HP:0001903 (Anemia)
Elevated inflammatory markers (CRP, ESR)	Laboratory abnormality	Near-universal	—	HP:0011227 (Elevated CRP — verify OAK term); HP:0003565
Positive blood cultures/bacteremia	Laboratory/microbiologic	Major Duke criterion	—	(Not typically HPO-coded; a laboratory/microbiologic finding)
Mycotic (infectious) aneurysm	Vascular complication	~2–10%	Can present late, sometimes after treatment	HP:0004944 (Aneurysm)

Quality-of-life impact: IE carries substantial acute morbidity (prolonged hospitalization, IV antibiotic courses of 4–6+ weeks, frequent cardiac surgery), and survivors — particularly those with embolic stroke, heart failure, or valve replacement — face lasting functional impairment; formal disease-specific QoL instrument data (EQ-5D/SF-36) are sparse in the IE literature relative to chronic diseases, reflecting its status as an acute, often curable infection rather than a chronic condition, though post-stroke and post-cardiac-surgery patients experience durable QoL decrements documented in the broader stroke/cardiac-surgery literature.

4. Genetic/Molecular Information

IE is not a monogenic disease — there are no "causal genes" in the OMIM/ClinVar sense analogous to a Mendelian disorder. Genetic information relevant to IE falls into three categories:

(a) Host susceptibility loci (modifier, not causal, and typically common variants of modest effect): - TLR2 (HGNC:11848) and TLR5 (HGNC:11851) polymorphisms — associated with increased IE susceptibility via impaired peptidoglycan/lipoteichoic-acid/flagellin sensing - IL6 (HGNC:6018) c.471+870G>A — associated with increased susceptibility - IL1B (HGNC:5992), IL10 (HGNC:6018... actually HGNC:5962), IL12B (HGNC:5970), TNF (HGNC:11892), SELE (HGNC:10718), ICAM1 (HGNC:5344) — inflammatory-response gene variants studied for association (PMID:25360655) - A dedicated GWAS of S. aureus native-valve IE (PMC5893849) found suggestive (not genome-wide-significant) chromosome-3 loci, indicating the field lacks a robustly replicated common-variant architecture and larger studies are needed - Functional consequence framing: these are population susceptibility/modifier alleles, not deterministic pathogenic variants — none currently meet ACMG/AMP pathogenicity criteria because there is no monogenic Mendelian trait to classify against

(b) Predisposing-condition genes (genes causal for the structural substrate, not for IE itself): e.g., FBN1 (Marfan syndrome, OMIM:154700), TGFBR1/TGFBR2 (Loeys-Dietz syndrome), genes underlying bicuspid aortic valve (NOTCH1, GATA5, SMAD6) and hypertrophic cardiomyopathy (MYH7, MYBPC3) — these create the anatomic nidus but are several causal steps removed from the infection itself.

(c) Pathogen-side molecular determinants — the mechanistically central "genetics" of IE lies in the microbial virulence factors, not the human genome: - Sortase A (SrtA) — a S. aureus transpeptidase that covalently anchors LPXTG-motif surface proteins (MSCRAMMs) to peptidoglycan; essential for surface display of adhesins - MSCRAMMs (Microbial Surface Components Recognizing Adhesive Matrix Molecules): ClfA (clumping factor A, binds fibrinogen), FnBPA/FnBPB (fibronectin-binding proteins A/B, bind fibronectin/fibrinogen/elastin and mediate both initial colonization and endothelial-cell invasion), and Cna (collagen-binding adhesin). "Experiments employing heterologous expression of the staphylococcal MSCRAMMs clumping factor A (ClfA) and fibronectin binding protein A (FnbA) in Lactococcus lactis suggest that these proteins mediate initial colonization and invasiveness, respectively, in staphylococcal IE." Polymorphisms in fnbA are associated with cardiovascular-device infection risk (PNAS PMID:21969557, PMC of PMID:21969557). - von Willebrand factor-binding protein (vWbp) and coagulase — staphylococcal factors implicated in vegetation formation, though a rat catheter-model study found only a "marginal role" for these specific factors in initiating vegetation (PMC7000203) - Streptococcal MSCRAMMs/pilus adhesins in Streptococcus gallolyticus (S. bovis group) — Acb (collagen-binding adhesin) and related pilus proteins (PMID:19717591, J Bacteriol) - Epigenetics: Limited data exist on valve-tissue epigenetic changes in IE specifically; transcriptomic (not epigenomic) profiling has been the dominant molecular-profiling approach (see below). - Chromosomal abnormalities: Not applicable to IE as an infectious process (no karyotypic/CNV etiology), aside from the CNVs/structural variants underlying some predisposing congenital cardiac lesions.

5. Environmental Information

Environmental/exposure factors: Contaminated injection drug paraphernalia (bacterial and fungal inoculation); indwelling foreign material (catheters, prosthetic valves, CIEDs) providing a surface for biofilm formation; healthcare exposures (hemodialysis, recent hospitalization, invasive procedures)
Lifestyle factors: Injection drug use is the dominant modifiable lifestyle risk factor, with a shifting demographic — "most opioid use disorder-associated IE hospitalizations [2016–2020] were among females, in stark contrast with IE due to other causes" — reflecting the opioid epidemic's changing face; poor dental hygiene; homelessness and body-lice exposure (risk factor specifically for Bartonella quintana IE, "trench fever" organism)
Infectious agents (primary etiology, detailed in §2): Gram-positive cocci (S. aureus, viridans/other streptococci, enterococci, coagulase-negative staphylococci) dominate; Gram-negative HACEK organisms and fungi (Candida spp.) are less common but clinically important; zoonotic/atypical agents (Coxiella burnetii, Bartonella spp., Brucella spp.) cause a meaningful fraction of culture-negative IE and require specific serologic/molecular diagnostics (indirect immunofluorescence for Coxiella, EIA/PCR for Bartonella).

6. Mechanism / Pathophysiology

Causal Chain (Initial Trigger → Clinical Manifestation)

Step 1 — Endothelial injury and NBTE formation (initiating, upstream): Endocardial trauma from turbulent blood flow (across a stenotic/regurgitant/bicuspid valve), mechanical irritation from a catheter or prosthetic material, or immune-complex/vasculitic injury exposes the subendothelial extracellular matrix (collagen, fibronectin, tissue factor). This activates platelets and the coagulation cascade, producing a sterile fibrin-platelet thrombus — non-bacterial thrombotic endocarditis (NBTE). As one review states: "Infective endocarditis is initiated by an endothelial injury that results in exposure of the subendothelial extracellular matrix that activates platelets and causes the formation of a fibrin-platelet clot" (Merck/StatPearls synthesis); "the damaged endocardium then serves as a nidus for platelet aggregation and activation of the coagulation cascade, resulting in sterile, nonbacterial thrombotic vegetations" (NBK557641).

Step 2 — Transient bacteremia and microbial adherence (trigger event): A bacteremic or fungemic episode (dental manipulation, IDU injection, catheter contamination, gut/mucosal translocation) delivers circulating organisms that adhere to the NBTE surface via pathogen-encoded MSCRAMMs (ClfA, FnBPA/B binding fibrinogen/fibronectin) — "subsequently, microorganisms in the blood adhere to the fibrin-platelet clot to initiate vegetation formation in infective endocarditis."

Step 3 — Bacterial proliferation, biofilm formation, and vegetation maturation (CELLULAR/MOLECULAR): Adherent organisms proliferate within the fibrin matrix, are shielded from host phagocytes and antibiotic penetration by the fibrin/platelet scaffold (biofilm-like protection), and continue to recruit platelets/fibrin, producing a mature, friable vegetation composed of fibrin, platelets, inflammatory cells, and dense microbial colonies.

Step 4 — Host innate immune activation (parallel, CELLULAR): Pathogen-associated molecular patterns (peptidoglycan, lipoteichoic acid via TLR2; LPS via TLR4) engage pattern-recognition receptors on monocytes/endothelium, triggering MyD88-dependent NF-κB signaling, pro-inflammatory cytokine release (IL-1β, IL-6, TNF-α), and NLRP3 inflammasome activation with caspase-1-mediated maturation of IL-1β/IL-18 — driving both local tissue inflammation and the systemic inflammatory/febrile response. Complement activation (membrane attack complex assembly) further amplifies endothelial NLRP3 inflammasome activity in IFN-γ-primed endothelium.

Step 5 — Local tissue destruction (TISSUE, downstream): Ongoing infection causes valve leaflet perforation, chordal rupture, and can extend beyond the valve annulus to form paravalvular/myocardial abscesses, pseudoaneurysms, or fistulae — mechanically producing valvular regurgitation/stenosis.

Step 6 — Systemic embolization and immune-complex deposition (ORGANISM, downstream): Fragments of the friable vegetation embolize to the brain (stroke, mycotic aneurysm), spleen, kidneys, and extremities (Janeway lesions), while circulating immune complexes deposit in skin (Osler nodes), retina (Roth spots), and glomeruli (immune-complex glomerulonephritis).

Step 7 — Hemodynamic decompensation and multiorgan complications (ORGANISM, terminal common pathway): Acute valvular regurgitation and/or myocardial abscess/conduction-system involvement (AV block) precipitate heart failure; sepsis, embolic stroke, and renal failure compound systemic decompensation — "heart failure and compromised hemodynamic status are identified as the dominant predictors for 30-day mortality."

Cell Types and Biological Processes Involved

Platelets (CL:0000233) — initial NBTE scaffold formation, aggregation
Endothelial cells (CL:0000115) — injury/dysfunction, NLRP3 activation, adhesion molecule (E-selectin/ICAM-1) upregulation
Monocytes/macrophages (CL:0000576/CL:0000235) — pathogen recognition, inflammasome activation, phagocytosis (often evaded within biofilm)
Neutrophils (CL:0000775) — recruited to vegetation, contribute to local tissue damage
Fibroblasts/myofibroblasts — organizing/healing response in chronic vegetations
Relevant GO Biological Process terms: GO:0007596 (blood coagulation), GO:0030193 (regulation of blood coagulation), GO:0002376 (immune system process), GO:0006954 (inflammatory response), GO:0043123 (positive regulation of I-kappaB kinase/NF-kappaB signaling), GO:0043312 (neutrophil degranulation), GO:0002250 (adaptive immune response — for immune-complex phenomena), GO:0007599 (hemostasis)

Molecular Profiling Data

Transcriptomics: "The Transcriptional Programme of Human Heart Valves Reveals the Natural History of Infective Endocarditis" (PMID:20126625) profiled gene expression in excised human IE valve tissue, characterizing the local transcriptional response and its temporal evolution during disease.
Proteomics/metabolomics/lipidomics: No large-scale disease-specific datasets identified in this search; represents a research gap relative to genomics/transcriptomics.
Genomic structural features: Not applicable at the host level (non-Mendelian); pathogen genomic epidemiology (e.g., S. aureus clonal complex typing, agr locus variants) is an active research area for virulence correlation.

7. Anatomical Structures Affected

Organ level: - Primary: Heart — endocardium, cardiac valves (mitral most common in native-valve left-sided IE overall; aortic valve predominant in bicuspid-valve-associated IE; tricuspid valve predominant in IVDU-associated right-sided IE), chordae tendineae, papillary muscles, interventricular septum (in VSD-associated IE), and prosthetic valve material/annular sewing ring - Secondary (embolic/immune complications): Brain (embolic stroke, mycotic aneurysm, abscess), spleen (infarct, abscess), kidney (infarct, immune-complex glomerulonephritis), lung (septic pulmonary emboli — classic in right-sided/tricuspid IE), skin (Osler nodes, Janeway lesions, petechiae), eye/retina (Roth spots), peripheral/visceral arteries (mycotic aneurysm), musculoskeletal system (septic arthritis, vertebral osteomyelitis/discitis) - Body systems involved: Cardiovascular (primary), nervous (embolic/inflammatory CNS complications), renal, immune, dermatologic, ocular, musculoskeletal

Tissue and cell level: - Valvular endothelium/subendothelial connective tissue — site of NBTE and infection - Vascular endothelium (systemic) — target of embolic and immune-complex injury - Renal glomerular basement membrane/mesangium — immune-complex deposition

Subcellular level: - Platelet cytoplasmic granules (release reaction feeding NBTE) - Endothelial cell plasma membrane (TLR/adhesion molecule expression), cytoplasm (NLRP3 inflammasome assembly), and, in host inflammatory cells, mitochondria (oxidative burst) - Relevant GO Cellular Component: GO:0005886 (plasma membrane), GO:0032991 (protein-containing complex, for the NLRP3 inflammasome), GO:0070062 (extracellular exosome, relevant to platelet-derived microparticles)

Localization/UBERON terms (suggested): - UBERON:0000948 (heart) - UBERON:0002332 (mitral valve) - UBERON:0002137 (aortic valve) - UBERON:0002136 (tricuspid valve) - UBERON:0002094 (endocardium) - UBERON:0000955 (brain) — embolic complications - UBERON:0002106 (spleen) - UBERON:0002113 (kidney) - UBERON:0001981 (blood vessel) — mycotic aneurysm

Lateralization: Left-sided IE (mitral/aortic) is more common overall and community-associated; right-sided IE (tricuspid, sometimes pulmonic) is strongly associated with IVDU and CIED lead infection.

8. Temporal Development

Onset: - Age of onset spans the full adult lifespan, with a marked shift toward older age over recent decades (see Epidemiology); pediatric IE is uncommon (estimated 0.43–0.69 cases per 100,000 children) but occurs mainly in children with congenital heart disease or indwelling catheters/central lines, typically school-age children and adolescents, more often male - Onset pattern: Classically dichotomized into acute (rapid, fulminant, typically S. aureus, high fever, rapid valve destruction, days to 1–2 weeks to presentation) and subacute (indolent, typically viridans streptococci or HACEK organisms, low-grade fever, weeks to months of nonspecific constitutional symptoms — historically termed "subacute bacterial endocarditis")

Progression: - Disease stages (informal, not a formal staging system like cancer): early localized valvular infection → local extension (annular abscess, fistula) → systemic embolic/immune-complex phase → multiorgan complications/sepsis - Progression rate: Rapid in acute S. aureus IE (valve destruction and hemodynamic collapse can occur within days); slow/insidious in subacute viridans-streptococcal or Coxiella/culture-negative disease (weeks to months, occasionally presenting as chronic Q fever endocarditis over years) - Disease course pattern: Typically a single acute/subacute infectious episode treated to cure with antibiotics ± surgery, though relapse (within ~6 months, same organism) and reinfection (new episode, often different organism, especially in IVDU/dialysis/prosthetic-valve populations) are well described; not classically relapsing-remitting in the autoimmune sense - Disease duration: Self-limited with appropriate treatment for most native-valve cases (4 weeks IV antibiotics); prosthetic-valve and complicated cases require 6+ weeks and often surgery; without treatment, IE is essentially uniformly fatal

Patterns: - Remission: Treatment-induced (antibiotics ± surgical source control); spontaneous resolution is exceedingly rare and disease is not considered self-remitting - Critical periods: The first 2 weeks of antibiotic therapy carry the highest risk of embolic events and hemodynamic decompensation, making this the critical intervention window for surgical timing decisions in patients with large/mobile vegetations or heart failure; the first 6–12 months post-prosthetic-valve-implantation is the critical period of highest risk for early PVE.

9. Inheritance and Population

Epidemiology

Global incidence: 3–10 per 100,000 population per year (PMID:31941729)
United States trend: Age-standardized incidence rate (ASIR) rose from 10.2/100,000 in 1990 to 14.4/100,000 in 2019 — a 41% relative increase; increase greater in men (45.8%) than women (34.1%); driven almost entirely by the 55+ age group (112.7% relative increase in that stratum), while incidence among 5–19 year-olds fell 36.6% over the same 30-year period (American Journal of Cardiology, 2023 analysis of Global Burden of Disease data)
Mortality: 30-day all-cause mortality ~10.4% in some cohorts; in-hospital mortality commonly cited 15–30% (up to ~18% in one large series, approaching 30% in early prosthetic-valve IE); one-year mortality approaching 40% in some series; post-treatment survival ~85–90% at 1 year and 70–80% at 5 years per ESC guideline synthesis

Genetic Etiology Parameters

Because IE is an acquired infectious disease rather than a Mendelian trait, classic Mendelian-genetics parameters (inheritance pattern, penetrance, expressivity, anticipation, germline mosaicism, founder effect, carrier frequency) do not directly apply. What is heritable/population-structured is host susceptibility (innate-immune gene polymorphisms noted in §4) and the structural cardiac lesions that predispose to it (which do follow AD/AR/multifactorial inheritance in their own right — e.g., bicuspid aortic valve shows a multifactorial/oligogenic pattern with ~9% familial recurrence and identified genes including NOTCH1).

Population Demographics

Sex ratio: Male predominance, ~3:2 in most series (range 3:2–9:1 depending on cohort/organism); notable recent reversal in opioid-associated IE, where most 2016–2020 U.S. hospitalizations were among females
Age distribution: Bimodal historically (rheumatic-heart-disease-associated young adults vs. degenerative-valve-disease-associated elderly), now heavily weighted toward older adults (55+) in high-income countries due to declining rheumatic fever and rising prosthetic valve/device use and healthcare-associated bacteremia; younger, IVDU-associated peak in some U.S. regions during the opioid epidemic
Geographic distribution: Regional disparities documented within the U.S. (Gender, Age, and Regional Disparities study, Am J Cardiol 2023); globally, Coxiella burnetii IE shows marked geographic clustering (Mediterranean basin, parts of the Middle East and Asia) reflecting Q fever endemicity; rheumatic-heart-disease-associated IE remains disproportionately common in low- and middle-income countries
Affected/at-risk populations: People who inject drugs, hemodialysis patients, patients with prosthetic valves/CIEDs, older adults with degenerative valve disease, patients with congenital heart disease (particularly bicuspid aortic valve)

10. Diagnostics

Clinical Tests

Blood cultures: Cornerstone of diagnosis. "Antimicrobial therapy should generally not be commenced until three sets of blood cultures have been taken; this will detect bacteraemia successfully in up to 98% of cases." LOINC-coded (e.g., LOINC:600-7 for blood culture)
Inflammatory/laboratory markers: CRP, ESR, procalcitonin (PCT — "strictly tied with S. aureus etiology" and "the best predictor of poor clinical outcome"), complete blood count (anemia, leukocytosis), rheumatoid factor (immune-complex marker), complement levels (low in immune-complex glomerulonephritis), urinalysis (hematuria/proteinuria)
Cardiac biomarkers (prognostic): NT-proBNP (independent predictor of in-hospital mortality, OR 14.9 in one study; levels <2926 pg/mL had 96.6% negative predictive value for favorable outcome), cardiac troponin, pro-adrenomedullin and copeptin (associated with worse prognosis)
Imaging:
Transthoracic echocardiography (TTE) — first-line
Transesophageal echocardiography (TEE) — higher sensitivity for vegetations/abscess, standard in suspected/complex cases; "both TTE and TEE can provide normal or inconclusive findings in up to 30% of cases, especially in patients with prosthetic devices"
Cardiac CT/CT angiography — best for assessing perivalvular abscess/pseudoaneurysm
¹⁸F-FDG PET/CT — recommended especially for possible prosthetic-valve IE, "to both detect valvular lesions and confirm the diagnosis," and best for cardiac device infection and extracardiac septic foci
Multimodality comparative performance: "Echocardiography performed best in the assessment of vegetations...MDCTA performed best in the assessment of abscesses, and FDG-PET/CT performed best in the assessment of cardiac device infection, extracardiac infectious foci, and alternative diagnoses"
Histopathology (surgical/autopsy specimens): Vegetation histology showing fibrin, platelets, inflammatory infiltrate, and organisms; valve tissue Gram stain and culture

Genetic Testing

Not applicable as a diagnostic modality for IE itself (non-Mendelian). Molecular diagnostics are pathogen-directed rather than host-genome-directed: - PCR/broad-range 16S rRNA sequencing and metagenomic/amplicon sequencing of excised valve tissue or blood — critical for culture-negative IE (fastidious/intracellular organisms) - Serology/EIA for Coxiella burnetii (phase I/II antibody titers — gold standard for Q fever endocarditis) and Bartonella spp. - In situ hybridization on valve tissue — newly incorporated in the 2023 Duke-ISCVID criteria

Clinical Criteria — the Duke/Duke-ISCVID Criteria

Modified Duke criteria (2000): Definite IE requires 2 major, or 1 major + 3 minor, or 5 minor criteria; major criteria = positive blood cultures (typical organism from 2 separate cultures, or persistently positive cultures) + evidence of endocardial involvement (echocardiographic vegetation/abscess/new dehiscence, or new valvular regurgitation); minor criteria include predisposing heart condition or IVDU, fever ≥38°C, vascular phenomena (emboli, mycotic aneurysm, Janeway lesions), immunologic phenomena (glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor), and microbiologic evidence not meeting major criteria. Sensitivity ~80% overall, "significantly lower in cases of prosthetic valve endocarditis."
2023 Duke-ISCVID criteria (PMID:37138445, Clinical Infectious Diseases 77(4):518–526, lead author Vance G. Fowler): Major revision adding (1) new microbiologic modalities — Bartonella EIA, PCR, amplicon/metagenomic sequencing, in situ hybridization; (2) advanced imaging — ¹⁸F-FDG PET/CT and cardiac CT; (3) intraoperative inspection as a new Major Clinical Criterion within a newly created surgical domain (added to the pre-existing microbiologic and imaging domains); (4) an expanded "typical organism" list, with certain pathogens counted as typical only in the presence of intracardiac prosthetic material; (5) simplified blood-culture timing requirements (removed the requirement for strict timing and separate venipuncture sites); (6) clarified predisposing conditions to explicitly include transcatheter valve implants and endovascular CIEDs. Reported sensitivity 89.4% vs. 87.9% for the 2015 ESC-modified Duke criteria in a comparative cohort.
Differential diagnosis: Non-bacterial thrombotic (marantic) endocarditis, Libman-Sacks endocarditis (SLE/antiphospholipid syndrome), rheumatic valvulitis, atrial myxoma, degenerative valve calcification with sterile vegetation-mimicking lesions, culture-negative "aseptic" post-infectious endocarditis.

Screening

No population-based screening program exists for IE (it is an acute infectious event, not amenable to presymptomatic screening); the closest analog is targeted surveillance/echocardiographic monitoring in known high-risk populations (e.g., IVDU with recurrent bacteremia, hemodialysis patients with recurrent access infections) and pre-procedural risk stratification for prophylaxis decisions (see Prevention).

11. Outcome/Prognosis

Survival and Mortality

30-day mortality: ~10.4% in one large contemporary cohort; up to 30% cited in other series
In-hospital mortality: ~15–30% overall, "approximately 18%" in one cited series, with early prosthetic-valve endocarditis carrying the highest mortality (~30%)
One-year mortality: approaching 40% in some cohorts
Post-treatment survival (ESC guideline synthesis): 85–90% at 1 year, 70–80% at 5 years
Sex/age trends in mortality are an active research area (JACC: Advances 2025, PMC12271061 — "Impact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income Countries")

Morbidity and Function

"Up to 50% of patients will require surgery" during the index hospitalization
Neurologic complications occur in 15–30% of cases, "up to 60% of patients experience neurological complications" when vegetations exceed 30mm
Acute valvular incompetence develops in approximately one-third of cases; intracardiac abscesses in ~14%; AV block in ~8%
Survivors of embolic stroke or requiring valve replacement face durable functional impairment (documented in general stroke/cardiac-surgery QoL literature; IE-specific disease-specific QoL instrument data are limited)

Disease Course / Complications

Cardiac: Acute heart failure/cardiogenic shock (leading mortality predictor), paravalvular abscess, fistula, conduction abnormalities/heart block, pericarditis
Neurologic: Ischemic embolic stroke, intracranial hemorrhage (including from mycotic aneurysm rupture), brain abscess, meningitis
Renal: Immune-complex glomerulonephritis, embolic renal infarction, acute kidney injury (from sepsis, nephrotoxic antibiotics, or hemodynamic compromise)
Vascular: Septic/mycotic aneurysms (any arterial bed), splenic infarct/abscess, septic pulmonary emboli (right-sided IE)
Musculoskeletal: Septic arthritis, vertebral osteomyelitis/discitis

Prognostic Factors and Biomarkers

Dominant predictors of mortality: heart failure/hemodynamic compromise, septic shock, uncontrolled local infection/periannular complications, S. aureus etiology, negative blood cultures, and failure to undergo indicated surgery
Prognostic biomarkers: NT-proBNP (OR 14.9 for in-hospital mortality), procalcitonin, CRP (specifically associated with embolic risk), cardiac troponin (s-cTnI showed highest single-marker accuracy for mortality prediction in one multimarker study), IL-6, TNF-α, pro-adrenomedullin, copeptin

12. Treatment

Pharmacotherapy

Antibiotic selection is organism- and susceptibility-directed, with prolonged parenteral courses (NCIT:C15986 Pharmacotherapy): - Streptococcal native-valve IE (penicillin-susceptible): Ceftriaxone 2g IV daily × 4 weeks, or ceftriaxone + gentamicin (synergy regimen) × 2 weeks - MSSA native-valve IE: Nafcillin/oxacillin or cefazolin × 6 weeks - MRSA native-valve IE: Vancomycin or daptomycin × 6 weeks - Enterococcal IE: Combination therapy — ampicillin (or penicillin G) plus an aminoglycoside (gentamicin) × 4–6 weeks (increasingly, ampicillin plus ceftriaxone dual beta-lactam regimens to reduce aminoglycoside nephrotoxicity) - Prosthetic-valve IE: Minimum 6 weeks, combination therapy typically including rifampin plus gentamicin (staphylococcal PVE) to address biofilm-associated organisms - Fungal (Candida) IE: Echinocandins (e.g., caspofungin, micafungin) or liposomal amphotericin B ± flucytosine as first-line, with fluconazole step-down; "no difference in either 42-day or 1-year mortality between those receiving an amphotericin B-based regimen vs those receiving an echinocandin-based regimen," and echinocandins are increasingly favored for their renal safety profile - Culture-negative/atypical organisms: Doxycycline ± hydroxychloroquine for chronic Coxiella burnetii (Q fever) endocarditis (often prolonged, sometimes lifelong, therapy); doxycycline-based regimens for Bartonella

Pharmacogenomics: Not a major axis of IE-specific precision therapy at present (unlike oncology); relevant PGx considerations are largely generic antibiotic-safety pharmacogenomics (e.g., vancomycin nephrotoxicity monitoring, aminoglycoside ototoxicity risk) rather than IE-specific gene-drug pairs in CPIC/PharmGKB.

Surgical and Interventional

Standard surgical indications (NCIT:C15329 Surgical Procedure / NCIT:C16186 Orthopedic-analog cardiac procedure term / more precisely valve-specific procedure terms): severe heart failure from valve dysfunction, uncontrolled infection (periannular abscess, persistent bacteremia despite appropriate antibiotics, fungal/highly resistant organisms), prosthetic-valve infection, invasion beyond the leaflets (abscess/fistula/pseudoaneurysm), recurrent systemic embolization despite antibiotics, and large mobile vegetations (classically >10mm with embolic events)
Emergency surgery (<24 hours) for cardiogenic shock; urgent surgery (within days) for progressive heart failure or uncontrolled infection
Valve repair preferred over replacement when feasible, especially mitral/tricuspid; allograft favored for aortic valve in the setting of annular abscess; choice between mechanical and bioprosthetic valve follows standard non-IE-specific criteria (PMID:31832353, AATS 2016 consensus guidelines)

Supportive and Rehabilitative Care

Hemodynamic support and management of septic shock/heart failure during acute treatment; anticoagulation management is individualized (embolic risk vs. hemorrhagic transformation risk, particularly in mechanical-valve patients with concurrent stroke)
Post-surgical cardiac rehabilitation and, where indicated, post-stroke rehabilitation (physical/occupational/speech therapy)

Experimental / Investigational

Bacteriophage therapy for refractory/multidrug-resistant staphylococcal or Gram-negative IE (case-report-level evidence, active investigational area)
Novel anti-biofilm and anti-adhesin (anti-MSCRAMM) therapeutic strategies targeting FnBPA/ClfA remain preclinical
Search of ClinicalTrials.gov identified ongoing interventional and observational trials (e.g., NCT06403839, evaluating preoperative dental screening to reduce IE risk in surgical valve-replacement patients)

Treatment Strategy

Treatment algorithms follow society guidelines (AHA/ACC and, more comprehensively and recently, ESC 2023): empiric broad-spectrum therapy pending cultures → organism-directed narrow-spectrum regimen once identified → reassessment for surgical indications throughout the antibiotic course, ideally via a multidisciplinary "Endocarditis Team" (cardiology, cardiac surgery, infectious disease, microbiology, sometimes neurology) — an ESC-endorsed structural recommendation
Two-phase inpatient/outpatient model: "the first phase of antibiotic treatment consists of 2 weeks of in-hospital parenteral treatment," during which surgery (if indicated) is performed, followed by completion of therapy (sometimes via outpatient parenteral antibiotic therapy, OPAT, for stable patients)

For each treatment class, suggested NCIT terms: NCIT:C15986 (Pharmacotherapy), NCIT:C15632 (Chemotherapy — n/a here), NCIT:C15329 (Surgical Procedure), NCIT:C15289 (Organ/valve replacement — Organ Transplantation is the closest existing generic NCIT class for valve replacement framing), NCIT:C15747 (Supportive Care), NCIT:C15315 (Rehabilitation).

13. Prevention

Prevention Levels

Primary prevention: Antibiotic prophylaxis before invasive dental procedures in defined high-risk patients (see below); good oral hygiene and routine dental care for all patients with predisposing cardiac lesions; harm-reduction interventions for people who inject drugs (sterile equipment, treatment for substance use disorder) to reduce inoculation events; prompt, adequate treatment of S. aureus bacteremia from any source to prevent secondary valve seeding; meticulous aseptic technique for prosthetic valve/CIED implantation and catheter care
Secondary prevention: Early recognition and treatment of bacteremia in high-risk patients; surveillance echocardiography in patients with recurrent bacteremia or known device infection risk
Tertiary prevention: Prompt surgical intervention when indicated to prevent progression to heart failure/embolic catastrophe; long-term follow-up echocardiography after treated IE to detect relapse or valve dysfunction

Prophylaxis — High-Risk Cardiac Conditions

Per AHA (2007 guideline, reaffirmed with no substantive changes by a 2021 AHA scientific statement) and the more recently strengthened 2023 ESC guidance (elevating dental antibiotic prophylaxis in high-risk patients to a Class I recommendation): prophylaxis is recommended only for patients with the highest-risk underlying cardiac conditions: - Prosthetic cardiac valve or prosthetic material used for valve repair - Previous history of infective endocarditis - Unrepaired cyanotic congenital heart disease, or repaired congenital heart disease with residual defects at or adjacent to a prosthetic patch/device, or during the first 6 months after complete repair with prosthetic material - Cardiac transplant recipients who develop valvulopathy - (Notably, common lesions such as isolated mitral valve prolapse or bicuspid aortic valve without other high-risk features are not indications for prophylaxis under current AHA guidance, though some literature notes ongoing debate about extending coverage to BAV/MVP patients)

Regimen: Prophylaxis is reasonable for dental procedures involving manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa; amoxicillin is first-line (single oral dose ~30–60 minutes before the procedure), with clindamycin, azithromycin, or cephalosporins as penicillin-allergic alternatives.

Screening/Genetic Counseling

Not applicable in the Mendelian sense; the closest analog is structural-cardiac-lesion screening (echocardiographic identification of bicuspid aortic valve, MVP) which informs prophylaxis eligibility and long-term surveillance rather than reproductive genetic counseling.

Public Health / Immunization

No licensed vaccine exists against the principal IE pathogens (S. aureus vaccine candidates have repeatedly failed in clinical trials); broader public-health measures include rheumatic-fever prevention programs (penicillin prophylaxis for rheumatic heart disease, reducing a major historical predisposing lesion in low/middle-income countries), harm-reduction services for injection drug use, and infection-control programs targeting healthcare-associated bacteremia (central-line-associated bloodstream infection [CLABSI] prevention bundles, dialysis-access care protocols).

14. Other Species / Natural Disease

Taxonomy of affected species: Domestic dogs (Canis lupus familiaris, NCBITaxon:9615) and cats (Felis catus, NCBITaxon:9685) both develop naturally occurring infective endocarditis, though it is uncommon; also described in horses and other domestic/companion animals.
Natural disease in companion animals: In dogs, "endocarditis infrequently occurs in small animals and is most often caused by bacterial infections," predominantly affecting the aortic and mitral valves. A UK retrospective series of 77 canine cases (2009–2019, PMC10099803/PMC10099803, J Small Anim Pract) and a separate 71-patient retrospective cohort documented a canine mortality rate of ~56%, with only about half of affected dogs surviving beyond two weeks. Common canine pathogens include Staphylococcus spp. (~27.5%, the most common isolate in one series), Streptococcus spp., Escherichia coli, and Bartonella spp. Complications mirror the human disease: left-sided congestive heart failure, arrhythmias, thromboembolic disease, immune-complex glomerulonephritis, and polyarthritis. Case reports also document unusual canine pathogens including Erysipelothrix rhusiopathiae and Bacillus amyloliquefaciens.
Veterinary relevance: IE is recognized as an important, high-mortality cardiac disease in veterinary internal medicine, generally underdiagnosed antemortem due to nonspecific presentation (fever, lethargy, lameness from immune-complex arthritis) preceding overt cardiac signs.
Comparative pathology: The fundamental NBTE-then-bacterial-seeding pathogenic sequence appears conserved across mammals, supporting the validity of large-animal (rabbit) and rodent (rat) models for translational study (see §15).
Zoonotic potential: Indirect — Bartonella henselae (cat-scratch disease agent) can cause IE in humans following exposure to cats, and Coxiella burnetii (Q fever), whose reservoir is livestock (sheep, goats, cattle) and their birth products, is a major zoonotic cause of human culture-negative IE; there is no evidence of direct dog-to-human or human-to-animal IE transmission — the shared risk is a common bacterial reservoir/exposure route rather than cross-species transmission of the disease itself.

15. Model Organisms

Model Types and Systems

The dominant experimental models of IE are surgically induced, catheter-based vegetation models in mammals, not spontaneous genetic models, because IE is fundamentally an infectious rather than a genetic disease:

Rabbit model: The classical and most widely used large-animal model. A polyethylene catheter is introduced (via carotid artery, into the left ventricle across the aortic valve for left-sided disease, or via jugular vein for right-sided disease) to mechanically damage the valve and induce sterile fibrin-platelet vegetations (mimicking NBTE), after which the animal is challenged intravenously with the test organism (classically S. aureus, viridans streptococci, or enterococci) to establish infective vegetations. A refined echocardiography-guided technique for creating right-sided S. aureus IE in rabbits without open surgery has been described (PMC3598207), improving reproducibility and reducing procedural morbidity. "The models described herein closely reproduced the pathogenesis and pathophysiology of right heart catheter-induced endocarditis in humans."
Rat model: Damage to the aortic valve and sterile vegetation formation is accomplished by insertion of a polyethylene catheter through the carotid artery into the left ventricle; "the rat model of endocarditis is a well-established experimental protocol which closely approximates human native-valve endocarditis," and has been used to dissect specific virulence-factor contributions (e.g., the marginal role of von Willebrand factor-binding protein and coagulase in vegetation initiation, PMC7000203).
Mouse model: A more recently developed induced S. aureus IE model exists, enabling use of the extensive mouse genetic/immunologic toolkit; MRI has been used to visualize S. aureus-induced vegetations non-invasively in mice (PMC4167704), and a dedicated induced-mouse-IE model paper describes its development and characterization (PMID referenced via ResearchGate summary of "Development of a mouse model of induced Staphylococcus aureus infective endocarditis").
In vitro/ex vivo systems: Heterologous expression systems (e.g., Lactococcus lactis expressing individual staphylococcal MSCRAMMs such as ClfA or FnbA) are used to isolate the contribution of single adhesins to colonization/invasiveness without the confounding of the full S. aureus virulence repertoire — an important reductionist in vitro/cellular model complementing the whole-animal catheter models.

Genetic Models

Because IE pathogenesis depends jointly on host vascular anatomy/hemodynamics and pathogen virulence factors, genetic manipulation is applied predominantly to the pathogen side (isogenic S. aureus mutants lacking specific MSCRAMMs — ClfA, FnBPA/B, sortase A — to test necessity/sufficiency for vegetation colonization) rather than to host germline engineering; host-side genetic models (e.g., TLR2-knockout mice) have been used in related cardiovascular-infection/sepsis contexts and are a logical extension for testing the innate-immune susceptibility genes identified in human association studies (§4), though a comprehensive host-genetic (knockout/transgenic) IE model survey was not surfaced in this search and represents a plausible research gap or an area needing more targeted follow-up querying of MGI/IMPC resources.

Model Characteristics

Phenotype recapitulation: Catheter-induced rabbit and rat models faithfully reproduce the two-step NBTE-then-bacterial-seeding pathogenesis, valve destruction, and (in some variants) systemic embolic phenomena seen in human disease, making them the field standard for testing novel antimicrobials, anti-adhesin therapeutics, and vaccine candidates.
Model limitations: These models require mechanical/surgical induction of the initiating endothelial injury rather than arising from spontaneous structural valve disease (e.g., naturally aging bicuspid valve degeneration), so they may not fully capture the chronic, degenerative-valve-driven pathogenesis increasingly dominant in elderly human IE; they also typically model a single high-inoculum bacteremic challenge rather than the repeated, lower-grade bacteremic exposures (e.g., from dental brushing) thought to seed some human cases.

Applications

These models are used to: (1) define the molecular determinants of bacterial adherence and vegetation colonization (MSCRAMM/sortase A studies); (2) evaluate novel and combination antimicrobial regimens for efficacy in sterilizing vegetations (a setting where poor antibiotic penetration into biofilm-protected vegetations is a central pharmacologic challenge); (3) test candidate anti-virulence or vaccine strategies; and (4) develop and validate non-invasive imaging approaches (e.g., MRI vegetation visualization) for translational diagnostic research.

Resources

Model-organism databases relevant to follow-up investigation: MGI (Mouse Genome Informatics) for any TLR2/TLR5/IL6 knockout strains relevant to host-susceptibility follow-up studies; standard rabbit/rat experimental-endocarditis protocols are documented in specialized infectious-disease methods literature (e.g., the Infection and Immunity/Antimicrobial Agents and Chemotherapy experimental-endocarditis model literature) rather than a centralized model-organism repository, reflecting the surgically-induced (not strain-distributed) nature of these models.

Summary of Suggested Ontology Term Bindings for Curation